Overview
Combination of Danazole With Berberine in the Treatment of ITP
Status:
Active, not recruiting
Active, not recruiting
Trial end date:
2021-06-30
2021-06-30
Target enrollment:
0
0
Participant gender:
All
All
Summary
A prospective, multicenter, open-label, Phase II, single arm, trial performed in 6 departments of hematology in ChinaPhase:
Phase 2Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Peking University People's HospitalTreatments:
Danazol
Criteria
Inclusion Criteria:1. Clinically confirmed immune thrombocytopenic purpura (ITP) newly diagnosed
2. Platelet count less than 30×109/L on two occasions or Platelets above 30×109/L
combined with bleeding manifestation
3. Subject is ≥ 18 years and ≤80years
4. Subject has signed and dated written informed consent.
5. Fertile patients must use effective contraception during treatment and observational
period
6. Negative pregnancy test
Exclusion Criteria:
1. Have an impaired renal function as indicated by a serum creatinine level > 2.0 mg/dL
2. Have an inadequate liver function as indicated by a total bilirubin level > 2.0 mg/dL
and/or an aspartate aminotransaminase or alanine aminotransferase level > 3×upper
limit of normal
3. Have a New York Heart Classification III or IV heart disease
4. Have a history of severe psychiatric disorder or are unable to comply with study and
follow-up procedures
5. Have active hepatitis B or hepatitis C infection
6. Have a HIV infection
7. Have active infection requiring antibiotic therapy within 7 days prior to study entry
8. Are pregnant or lactating women, or plan to become pregnant or impregnated within 12
months of receiving study drug
9. Previous treatment with rituximab
10. Previous splenectomy
11. Had previous or concomitant malignant disease
12. Not willing to participate in the study.
13. Expected survival of < 2 years
14. Intolerant to murine antibodies
15. Immunosuppressive treatment within the last month
16. Connective tissue disease
17. Autoimmune hemolytic anemia
18. Patients currently involved in another clinical trial with evaluation of drug
treatment